is currently solvent and making every effort to stay that way.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
many7s,
"I don't remember seeing this posted here ... "
It's there... post #41260
Doesn't hurt to remind folks tho- especially seeing that the workshop took place today...
Theo
News:
http://biz.yahoo.com/iw/060216/0110067.html
Press Release Source: DNAPrint Genomics, Inc.
South Louisiana Serial Killer Workshop to Be Presented at the American Academy of Forensics Science (AAFS) Annual Meeting on February 20, 2006 in Seattle, Washington
Thursday February 16, 7:00 am ET
SARASOTA, FL--(MARKET WIRE)--Feb 16, 2006 -- DNAPrint Genomics, Inc. (OTC BB:DNAG.OB - News) today announced that Dr. Matthew Thomas, Senior Scientist, is a scheduled speaker at the South Louisiana Serial Killer Workshop at the AAFS Annual Meeting on February 20, 2006 in Seattle, Washington. Dr. Thomas will explain DNAPrint Genomics' role in focusing investigation efforts towards the correct suspect, Derrick Todd Lee, in the South Louisiana Serial Killer case. Dr. Thomas's presentation will explain the science behind the DNAWitness(TM) product and demonstrate the process that resulted in test results reflecting Derrick Todd Lee's 85% Sub-Saharan African ancestry. This information was instrumental in focusing investigation efforts on appropriate suspects. The refocused investigation resulted in an arrest less than two months after DNAPrint Genomics provided the information and the suspect was ultimately convicted.
ADVERTISEMENT
The American Academy of Forensic Sciences is one of the world's largest and most renowned organizations of forensic scientists, with nearly 6,000 members in 57 countries. The annual meeting involves presentation of scientific papers and workshops designed to keep forensic scientists on the cutting edge of solving crime. One such workshop at this year's meeting involves a very complex, multifaceted investigation, which culminated in the apprehension and conviction of a serial killer. The experts involved in the case, including an investigator, several scientists, the profiler and legal experts, will come together to share their expertise and learning experiences, in the hopes of educating attendees so they can solve similar crimes more efficiently in their home jurisdictions.
In 2002 and 2003, murders of six victims were linked to a single assailant in Southern Louisiana. Multiple agencies were involved in the investigation and eventual prosecution of the cases, culminating in the death penalty sentence of Derrick Todd Lee in 2004. The hunt for the serial killer generated considerable media coverage, and resulted in wide sweeping effects to policy, legislation and funding. A variety of approaches were taken in the forensic investigation and prosecution of the crimes, including a blending of new technologies and trusted older techniques. The investigative use of databases generated unique leads when applied to the field of physical matching and comparison. A variety of DNA analytical methods, techniques, and applications were employed to link crimes together, eliminate suspects, implicate Lee, and bring novel investigative information to the serial killer task force, including ancestry determination which demonstrated that he was 85% African.
"The successful outcome of the Louisiana Serial Killer case in 2003 was a milestone for our DNAWitness forensic technology and brought nationwide attention to DNAPrint's capabilities in helping to solve complex crimes," stated President and Chief Executive Officer Richard Gabriel. "Since that time, DNAWitness or Retinome(TM) technologies are currently being utilized in more than 100 cases worldwide. Retinome(TM) provides an accurate inference of iris (eye) color from the measurement of proprietary single nucleotide polymorphisms (SNPs) distributed throughout the human genome and is a further advancement of DNAWitness technology. We are proud of our role in this investigation and we believe that there are many cases that would benefit from the application of our forensic technologies."
The forensic community will benefit by learning the keys to success, and avoiding the pitfalls, in large, multidiscipline, multiple-murder investigations. Techniques learned will be immediately employable by forensic scientists, investigators and administrators in their own jurisdictions and casework. The forensic community and society as a whole will benefit through protection of individuals' rights by rapid exoneration of innocent suspects, the increased public safety resulting from early apprehension of serial predators, and the reduced-cost benefit of an effective investigation using the latest technology.
About DNAPrint Genomics, Inc.
DNAPrint Genomics, Inc. (www.dnaprint.com) is a developer of genomics-based products and services in two primary markets: biomedical and forensics. DNAPrint Pharmaceuticals, Inc., a wholly owned subsidiary, develops diagnostic tests and theranostic products (drug/test combinations) using the Company's proprietary ancestry-informed genetic marker studies combined with proprietary computational modeling technology. Computational Biology and Pharmacogenomics services are also offered externally to biopharmaceutical companies. The Company's first theranostic product is PT-401, a "Super EPO" (erythropoietin) dimer protein drug for treatment of anemia in renal dialysis patients (end stage renal disease). Pre-clinical and clinical development of all the Company's drug candidates will benefit from simulated pre-trials to better design actual trials and are targeted to patients with a genetic profile indicating their propensity to have the best clinical response. DNAPrint is proud of its continued dedication to developing and supplying new technological advances in law enforcement and consumer ancestry heritage interests. Please refer to www.dnaprint.com for information on law enforcement and consumer applications which include DNAWITNESS(TM), RETINOME(TM), ANCESTRYbyDNA(TM) and EURO-DNA(TM). DNAWitness-Y and DNAWitness-Mito are two tests offered by the Company. The results from these tests may be used as identification tools when a DNA sample is deteriorated or compromised or other DNA testing fails to yield acceptable results.
Forward-Looking Statements
All statements in this press release that are not historical are forward-looking statements. Such statements are subject to risks and uncertainties that could cause actual results to differ materially from those projected, including, but not limited to, uncertainties relating to technologies, product development, manufacturing, market acceptance, cost and pricing of DNAPrint's products, dependence on collaborations and partners, regulatory approvals, competition, intellectual property of others, and patent protection and litigation. DNAPrint Genomics, Inc. expressly disclaims any obligation or undertaking, except as may be required by applicable law or regulation, to release publicly any updates or revisions to any forward-looking statements contained herein to reflect any change in DNAPrint's expectations with regard thereto or any change in events, conditions, or circumstances on which any such statements are based.
Contact:
Company Contact:
Richard Gabriel
CEO and President
941 366-3400
-or-
Ron Stabiner
The Wall Street Group, Inc.
212-888-4848
Source: DNAPrint Genomics, Inc.
Yep, kinda confirms it doesn't it?
Manysevens,
Know how you feel, I'm still "green" for the moment and continuing to hold all shares as well. I can't help but feel we {DNAG} are on the cusp of finally breaking out and gaining legitimacy in the investment world.
My intuition for now, however, is that volume will continue to recede as before and we will drift down to the 0.021 level again. {at least until more news arrives} The only advantage to momos like this is that as others are drawn into the game, the base support tends to get stronger. The only caveat is I don't believe all the bagholders got their money out- this time OR last time. Both these runs were followed by true PRs. Problem is is that the PRs just weren't lucrative enough to propel the pps high enough or long enough for the momo to fully play out and subsequently stalled out before complete fruition {for the front-runners that is}. I'm equally convinced that when we are in line for truly good news {i.e., self sustaining revenues, humungogigantic sales, buyouts, and etc.}, then we will see rapid pps appreciation and not this 20+ million in volume and only a pps rise to a nickel. No, when "the street" gets wind of real meat and potatoes type news, the first few million shares will tell you that we are indeed climbing for real. That's what I'm waiting for. I've got nothing against taking profits- that's how I managed to bring my ACPS down to 0.022 even carrying shares over from the R/S. Hey, like I've said and one of my favorite posters {Jim B} has said over the years- "Go to the dance but dance close to the door."
Theo
Gotta go back to work tomorrow. Hopefully DNAG can demonstrate significant cash infusion{s} by any other means than toxic financing arrangements and do it soon...
I dunno Jeeves, this played out pretty much verbatim as the other "run" late last year... In other words, they look suspiciously alike in most respects i.e., two day run with a HOD reached very early in the run of the second day followed with steady leeching all the way back down and then some. This has MOMO written all over it again. We continue to getting "played." What say you Jeeves??
Theo
Several trading days in early and late Novemeber with out-of-the-blue aberrant {large} trading volumes at the 0.015-0.018 level reaching just shy of a nickle {?0.044} intraday. Appeared to be classic front loading but with an interesting twist. Without the expected follow-up news {I think is what they were counting on} to help them out, the boys instead got caught with their proverbial pants down unable to extract their positions without taking a financial hit. So granted, perhaps a full double is a bit of a reach currently, but I suspect from watching the size of the blocks hitting the Bid today that there are traders from that time period shedding some of thier positions yesterday and today. Speaking of which, the Bid is getting hammered even as we speak.
I guess we wait it out and see if DNAG does have anything to offer us soon to justify the irrational exuberance {crazy volume} we seem to have {again} achieved.
Theo
Easy double for a lot of folks @0.03- therefore betting it's going to take a little time to clean them up and establish a new base before moving up. Of course, that assumes the catalyst for advancement is legit and not a momo run. I can't help but believe what with all DNAG is doing that there isn't something ready soon for the investment community to embrace whole-heartedly.
FWIW current stats as of 11:19:39:
Bid 0.0294
Ask 0.0295
Last ticks +-=-+===
Last trade 0.0295 {5000}
Volume 18,250,461
Closing volume 26,755,603 Time 16:00.24
Last 0.0266 5,500
Bid 0.0267
Ask 0.0269
For the day UP 23.72%
Subject to change given the unusual heavy volume there may be some amended trades later tonight- most likely out-of-sequence adjustments. Interesting to see what tomorrow brings. Gap? Retrace?
volume 21,694,593
STW,
While you may be correct, I would still like you to proffer "facts" to back your statements. Much as your fellow dissenters would demand from the "pumper" gallery were they to make such broad claims. I'm not interested in comparisons or "my brother in-law works for the FDA...", or any other "JMHO" claims. Just what proof do you possess that the rest of us don't in your claims that:
1} All of these drugs need to make it through testing and be approved by the FDA.
You know for a fact that "ALL of these drugs... be approved by the FDA.
2} Most of DNAG's "drug compounds" are in the very early stages.
You know for a fact that "most...are in the very early stages?
3} They are years away from FDA approval.
You know for a fact that DNAG is "years" away...?
These are not trick questions nor are they to be misconstrued as being sarcastic, belittling, or otherwise demeaning in any way. I really want to know. If your statements are accurate then I really will reconsider my position here in DNAG. Thanks!
Theo
Yep, I show a trade of 30K going through @0.022 jumping both Bid and Ask at the close. Not quite sure how that happened unless it's an "out-of-sequence" trade from earlier today. I didn't watch anything today so I have no idea if DNAG even made it to .022 earlier.
NEWS: DNAPrint Genomics' Ancestry Test Capabilities Noted in Newsweek Cover Story
http://biz.yahoo.com/iw/060203/0108560.html
Press Release Source: DNAPrint Genomics, Inc.
DNAPrint Genomics' Ancestry Test Capabilities Noted in Newsweek Cover Story
Friday February 3, 7:00 am ET
SARASOTA, FL--(MARKET WIRE)--Feb 3, 2006 -- DNAPrint Genomics, Inc. (OTC BB:DNAG.OB - News) today announced that the Company's AncestrybyDNA(TM) technology was cited in the cover story of this week's edition of Newsweek magazine in an article focusing on the growing use of DNA testing to understand family lineage and to answer questions about ancestry.
ADVERTISEMENT
The magazine's cover for the edition dated February 6 featured the headline "Genes & Family/What Science Can Tell You About Your History And Your Health." The story on the inside was headlined "DNA Testing: In Our Blood," and went on to say that "History lives in our genes. The DNA in each of our cells not only dictates the color of our eyes, it also contains the footprints of our ancestors." The article also mentioned that DNAPrint Genomics specializes in DNA technology for determining a person's ancestry.
Newsweek focused on the growing popularity of DNA testing and how it is giving families surprising glimpses into their past. The author of the article, Claudia Kalb, who was assisted by contributing editor Karen Springen, took the AncestryByDNA(TM) tests offered by DNAPrint Genomics. After receiving the results of the tests, they expressed to DNAPrint Genomics their surprise about details of their ancestry that they did not expect.
The article also mentions Debra Anne Royer, a client of DNAPrint's Trace Genetics subsidiary, who discovered that her maternal ancestry was Native American, providing her important and satisfying knowledge since she was an adopted child. She had always wondered about her background because she often was asked if she were Iranian or Cambodian due to her darker skin and nose characteristics. Newsweek journalists interviewed three other clients of DNAPrint and its Trace Genetics subsidiary, all of whom expressed surprise at their newly founded knowledge about their ancestry.
The article noted that Trace Genetics has a large database of Native American DNA samples. Following publication of the article, DNA Print President and Chief Executive Office Richard Gabriel explained in a statement how this process works. "Native American individuals belong to one of five major maternal lineages or haplogroups, A, B, C, D or X," he explained. "If Trace Genetics' Worldwide Ancestry-Mito test reveals that an individual belongs to one of the five Native American lineages, then we can run a Native American Mito Upgrade. The Mito Upgrade compares the client's mtDNA sequence against the Company's extensive Native American mtDNA database to identify geographic and tribal matches within the Americas."
Mr. Gabriel noted that there is no guarantee of a tribal match, but DNAPrint provides individuals information about whether their DNA is similar to those who claim to have tribal associations. "Having the DNA match does not prove that the client belongs to that tribe; it simply suggests the customer shares a distant common ancestor with individuals in the matched tribe and possibly non-sampled neighboring tribes," he said.
About DNAPrint Genomics, Inc.
DNAPrint Genomics, Inc. (www.dnaprint.com) is a developer of genomics-based products and services in two primary markets: biomedical and forensics. DNAPrint Pharmaceuticals, Inc., a wholly owned subsidiary, develops diagnostic tests and theranostic products (drug/test combinations) using the Company's proprietary ancestry-informed genetic marker studies combined with proprietary computational modeling technology. Computational Biology and Pharmacogenomics services are also offered externally to biopharmaceutical companies. The Company's first theranostic product is PT-401, a "Super EPO" (erythropoietin) dimer protein drug for treatment of anemia in renal dialysis patients (end stage renal disease). Pre-clinical and clinical development of all the Company's drug candidates will benefit from simulated pre-trials to better design actual trials and are targeted to patients with a genetic profile indicating their propensity to have the best clinical response. DNAPrint is proud of its continued dedication to developing and supplying new technological advances in law enforcement and consumer ancestry heritage interests. Please refer to www.dnaprint.com for information on law enforcement and consumer applications which include DNAWITNESS(TM), RETINOME(TM), ANCESTRYbyDNA(TM) and EURO-DNA(TM). DNAWitness-Y and DNAWitness-Mito are two new tests offered by the Company. The results from these tests may be used as identification tools when a DNA sample is deteriorated or compromised or other DNA testing fails to yield acceptable results.
Forward-Looking Statements
All statements in this press release that are not historical are forward-looking statements. Such statements are subject to risks and uncertainties that could cause actual results to differ materially from those projected, including, but not limited to, uncertainties relating to technologies, product development, manufacturing, market acceptance, cost and pricing of DNAPrint's products, dependence on collaborations and partners, regulatory approvals, competition, intellectual property of others, and patent protection and litigation. DNAPrint Genomics, Inc. expressly disclaims any obligation or undertaking, except as may be required by applicable law or regulation, to release publicly any updates or revisions to any forward-looking statements contained herein to reflect any change in DNAPrint's expectations with regard thereto or any change in events, conditions, or circumstances on which any such statements are based.
Contact:
Company Contact:
Richard Gabriel
CEO and President
941-366-3400
-or-
Ron Stabiner
The Wall Street Group, Inc.
212-888-4848
Source: DNAPrint Genomics, Inc.
I use Windows Registry Repair Pro- shareware from Tucows- free trial then you have to buy- I did.
Theo
GS- If I'm not mistaken didn't Cramer give a time frame of "200 by June"?? I can't seem to find a confirmation of the time frame on-site {Thestreet}, but, I wrote it down in my "MadMoney note journal" I leave by the T.V. ;) Ring a bell with anyone?
TIA
Theo
I dunno and like you and every poster here I would dearly love to be "in the loop" with Frudakis & Co and pull up a chair next to Gabriel or Stabiner when they write one of these PRs and ask them "What the crap does this mean?", but alas, it's not to be. Therefore we can only speculate. Not that your argument is without merit, on the contrary, very reasonable ponderings as are Frogdreamings. I don't have the answers.
Theo;-/
80spitfire,
Not having seen the post you are referring to I can only venture a guess based on the facts as you present them. A stock other than the one for which a board was created would/will be defined as "spam". Your stock tip no matter how innocuous your intentions would still be classified as "spam". Seem petty? Perhaps but turn it around. If every stock-specific board employed an open door policy, then what would be the sense or reason for having stock-specific boards in the first place?
Quite honestly, I like open topic boards {i.e., The Golden Lists, Zeeves, and etc..} and will gloss over them looking for tidbits of info. However, I'm equally annoyed when I see somebody pushing their "favorite" stock on a stock-specific board. {I don't know that that is what you did as I didn't see your post and I'm guessing as to the content remember? ;)}
Anyway, that's how I would view it based on the above and that's my "take" on it.
Theo
Frogdreaming,
No, I can't because I highlighted the entire paragraph and the area the piqued my interest was the following:
"... providing the kind of validation that we believe the U.S. Food and Drug Administration (FDA) is seeking for its clinical trials data,.."
-leads me to believe that DNAG is actively {currently} working with the FDA on clinical trials and not just working on them.
Sorry, can't help you with your specific question.
Theo
Before I take off for awhile- just an update FWIW:
Bid= .0183
Ask= .0185
Vol= 1,337,250
Well it came out positive with 900K in BUYS, but it only took 100+K to drive it back down... Shouldn't be surprised I guess. Didn't take the time to see who {which MM} it was but someone{s?} were holding humongus amounts of shares to sell as the lop-sided Bid/Ask was showing during the buying at the open this a.m. packet sizes of 100/50.
Anyway, day off so I get to hang around the 'ol homestead and check out potential option plays and generally make a nuisance of myself around here and abroad... Be back later!
Theo
It seems there are a few folks out there that apparently like the news as volume currently stands at 909,750 and the Bid is .0194 and the Ask is .0195. We'll see what the end of the day brings... ;)
Theo
NEWS:
http://biz.yahoo.com/iw/060131/0107948.html
I've highlighted a paragraph near the bottom I think may be of special interest:
Press Release Source: DNAPrint Genomics, Inc.
DNAPrint Genomics Expands High-Throughput Genotyping Capacity
Tuesday January 31, 7:00 am ET
SARASOTA, FL--(MARKET WIRE)--Jan 31, 2006 -- DNAPrint Genomics, Inc. (OTC BB:DNAG.OB - News) today announced the expansion of the Company's high-throughput genotyping capacity from 1.3 million to more than 3.9 million genotypes per day.
ADVERTISEMENT
"Multiplexing and advanced automation protocols provide the flexibility to process large or small genotyping studies without compromising cost per genotype," stated DNAPrint Genomics President and Chief Executive Officer Richard Gabriel. "Increasing high-volume throughput advances our ability to determine genotypes at economical costs to our customers and business partners. Coupled with our population ancestry technology, we can achieve better research results at a business-smart price."
The increase in processing capacity particularly targets the pharmaceuticals and healthcare market. It enables the Company to process clinical trials samples to ensure that patient population groups are accurately categorized, and perform large scale genotyping work for the various industries interested.
DNAPrint Genomics Founder and Chief Scientific Officer Tony N. Frudakis, Ph.D., noted that the Company has key advantages over other laboratories offering genotyping services. "We are unique in our expertise in population structure analysis using our Ancestry Informative Markers (AIM)," said Dr. Frudakis. "We can demonstrate to our customers that failure to understand the ancestral or biological structure of their study population can significantly confound and even compromise genetic studies. We offer a unique approach to maximizing the probability of success in pharmacogenetic, predisposition, risk profiling and susceptibility studies that many companies are pursuing alongside drug and diagnostics development."
DNAPrint has genotyping facilities at its Sarasota headquarters and at laboratories in Richmond, Calif., and Toronto, Canada, which utilize sophisticated equipment manufactured by Beckman Coulter and Illumina, Inc. The U.S. laboratories are genotyping with the ultra sensitive and robust GenomeLab SNPstream from Beckman Coulter while the Toronto lab is equipped with the Illumina bead machine and is also offering HAP MAP SNP genotyping services.
"Results from the GenomeLab SNPstream from Beckman Coulter are 99+% reproducible, providing the kind of validation that we believe the U.S. Food and Drug Administration (FDA) is seeking for its clinical trials data," Dr. Frudakis noted.
About DNAPrint Genomics, Inc.
DNAPrint Genomics, Inc. (www.dnaprint.com) is a developer of genomics-based products and services in two primary markets: biomedical and forensics. DNAPrint Pharmaceuticals, Inc., a wholly owned subsidiary, develops diagnostic tests and theranostic products (drug/test combinations) using the Company's proprietary ancestry-informed genetic marker studies combined with proprietary computational modeling technology. Computational Biology and Pharmacogenomics services are also offered externally to biopharmaceutical companies. The Company's first theranostic product is PT-401, a "Super EPO" (erythropoietin) dimer protein drug for treatment of anemia in renal dialysis patients (end stage renal disease). Pre-clinical and clinical development of all the Company's drug candidates will benefit from simulated pre-trials to better design actual trials and are targeted to patients with a genetic profile indicating their propensity to have the best clinical response. DNAPrint is proud of its continued dedication to developing and supplying new technological advances in law enforcement and consumer ancestry heritage interests. Please refer to www.dnaprint.com for information on law enforcement and consumer applications which include DNAWITNESS(TM), RETINOME(TM), ANCESTRYbyDNA(TM) and EURO-DNA(TM). Recently announced and as a part of the Company's Trace Genetics acquisition, DNAWitness-Y and DNAWitness-Mito are two new tests that can be used as an identification tool when other DNA testing either fails to yield results or the sample might be too deteriorated.
Forward-Looking Statements
All statements in this press release that are not historical are forward-looking statements. Such statements are subject to risks and uncertainties that could cause actual results to differ materially from those projected, including, but not limited to, uncertainties relating to technologies, product development, manufacturing, market acceptance, cost and pricing of DNAPrint's products, dependence on collaborations and partners, regulatory approvals, competition, intellectual property of others, and patent protection and litigation. DNAPrint Genomics, Inc. expressly disclaims any obligation or undertaking, except as may be required by applicable law or regulation, to release publicly any updates or revisions to any forward-looking statements contained herein to reflect any change in DNAPrint's expectations with regard thereto or any change in events, conditions, or circumstances on which any such statements are based.
Contact:
Company Contact:
Richard Gabriel
CEO and President
941 366-3400
-or-
Ron Stabiner
The Wall Street Group, Inc.
212-888-4848
Source: DNAPrint Genomics, Inc.
Soooooooo.... Jeeves- Is the sponsored research and a field-exclusive licensing agreement with Harvard the "BIG" February news you were promulgating here awhile back? Or, are you suggesting "more news to come" is the more meat and potatoes kind of news that's still in the offing? I noticed that the front-runners didn't budge on this tidbit prior to the release so I'm venturing a guess that the impetus that drove the volume back in December still hasn't materialized or the horribly staged momo they initiated blew up in their faces and they just cant extract themselves now without taking a continued hit in the pocket book. Just what, based on your claimed clairvoyant abilities, is next on our Hit Parade Jeeves? Better yet, just what is it the "boyz" are waiting for???
Theo
Okay Jeeves,
What happened to "this is my last post till the BIG ONE. THE DUCKS ARE IN LINE!!"
If nothing else Jeeves, you break up the monotony. Don't ever change... :)
Theo
Google Alert News: "...... for a mere $219. Just send a swab to DNAPrint's Ancestry..."
http://www.columbiaspectator.com/vnews/display.v/ART/2006/01/20/43d073b10bbff
Test-Tube Identities
Color Commentary
By Candyce Phoenix
January 20, 2006
What are you? It’s a question I’ve been asked on more than one occasion. Most of the time I just say, “light-skinned black.” I used to think I said it because it was too much trouble to go into all the many heritages coursing through my veins. Now I know it’s because I’m not entirely sure what I am.
Most people guess my ethnicity based on where I am. In Harlem, I’m black. In a Latino neighborhood in DC, an elderly Hispanic lady spoke to me in Spanish and was shocked when I couldn’t understand her. She demanded to know where I was from, insisting that I must have been from the Dominican Republic rather than from up the street. She then proceeded to deride me for adopting “gringo” ways and denying my heritage.
My senior year of high school, I pulled out my track team picture and repeatedly counted the number of black people, every time coming up one person short. Then it occurred to me that I hadn’t counted myself, because I had blended in with my white teammates.
By this time, I really started to wonder about my racial composition. As it turns out, I’ve got everything from Chinese to Native American, Irish, German, Latino, and black heritage. There are probably a few more I don’t remember or don’t know about, but I’m clearly a mixed bag.
My family tree’s a little murky, so I’ve been trying to figure out another way to determine my ancestry. After a little research, I discovered that I could have a full DNA diagnostic test done for a mere $219. Just send a swab to DNAPrint’s Ancestry by DNA and get a chart for the answer to “what are you?”
It’s an interesting proposition, but to be quite honest, I’m a little disturbed. Here I am thinking that race is solely a social construct, that eugenics is nonsense, and that advancing the notion that there are genetic differences in the races puts one clearly in the same camp with Nazis. Then I hear that I can fork over a couple of C-notes and find out exactly what race(s) I am.
To top it all off, a genetic bombshell dropped last semester when scientists claimed to have discovered the genetic difference that created white skin after the first people migrated from Africa.
But it’s all harmless, right? Just genuine scientific inquiry?
I can’t pretend to know a scientist’s motivation for this search and discovery, and I can’t pretend to know anything about the science behind this. What I do know is that we’ve already seen how this discovery has been appropriated to advance one racial agenda or another. Some people have called this difference a mutation, some an adaptation, some an evolution, each term just as loaded as the others. Mutation implies that white people are freaks of nature; adaptation, the most neutral term, implies that neither is better than the other, but just better suited for their respective environments. Evolution implies that white people are a higher life form than black people. All of this flies in the face of the often repeated mantra: the only difference between the “races” is skin color and race is a social construction.
Historical survey will prove that it is all social. A simple look at that US Census throughout time shows the ever-changing racial categories. In each case where the Census changed its accounting of race, the alteration was motivated not by scientific discovery, but by social pressure. This was particularly noticeable when the Census began allowing people to mark more than one race in 2000, acknowledging that few people fit neatly into any one box.
The genetic advances regarding race are frightening not because of the debate of whether they are scientifically sound, but because of whether they are socially sound. If social relationships were as simple as science, we could easily map out all the racial possibilities, pick our box and be done with it. We’d be like animals, choosing lion or tiger, or when things get confusing, liger or tion.
But obviously the realities of race are not so clear cut, and they don’t confine themselves to biological classification. Mark Batzer, a geneticist at Louisiana State University, said, “Races do exist, and they have some biological meaning.” If we could leave it at that, perhaps we could all accept racial DNA. But races have social meaning too. Saying that there are legitimate genetic differences and definitions opens the door for people such Richard Herrnstein and Charles Murray to write a book like The Bell Curve, advancing the idea that differences between the races account for IQ, social, and economic disparities.
Clearly, this is an extremely slippery slope. If there are legitimate genetic differences between the races, then by all means, we should explore them. The problem is that in our society, when it comes to race, different doesn’t just mean different. Different has been extrapolated to erect hierarchies in which one group cannot just be different from another, but it must be either better or worse. If we could learn to see differences absent value judgements, perhaps these discoveries would not be so problematic.
I haven’t decided if I’m going to fork over my money and a swab to determine my ancestry, but I do know that the fact that this is possible scares me. It’s not too far to jump from this to eugenics. Do we really want to be in the business of validating what so many have worked so hard to disprove? Social conflict should never stand in the way of scientific advancement, but we cannot allow scientific advancement to stand in the way of social progression.
The author is a Columbia College junior majoring in Comparative Ethnic Studies. Color Commentary runs alternate Fridays.
Hi David,
Sorry I can't help you with the OS as I don't routinely check. I'm surprised that no one else has responded as I'm sure I've seen other posts here with the latest???
How 'bout it? Anyone out here with the latest OS stats?
Theo
Yeah STW, I can see where you might confuse the word 'thought' with the word 'hope'. Happens all the time.
Save your couch analysis for somebody who buys into it STW, I have no need for a "scapegoat" nor do I "need" to vent. Sheesh, where do you people come from??
dr f,
Reread the post doc. I never stated that I HOPE that jeeves ...will eventually "get lucky" . Nor did I day anything about the "long termers" recouping their losses. I, in fact, poked fun again at Jeeves's relentless mantra of "NEWS IS COMING". I stated that I personally think that any price below 2 cents is a bargain like the chartist Snap Hook stated in his post and the one I referred to. The mention of Jeeves was tongue-in-cheek cause he will get lucky and be right someday.
"Have you considered the simple fact that the pps of this stock closed at .018 today?"
Considered it?!?!?
The majority of my post was speculating on the attempted run up of a few weeks ago and the possible connection between those clowns and the sudden appearance of block selling yesterday and today. How much more could I "consider" it?
Theo
Volume was/has been really light for some time now but the past two days it appears as if some seller{s} have dumped some larger blocks. Maybe the players from the "group" that tried to run us a few weeks ago and got caught in a stall are now tired of waiting and decided to bail out for whatever they could get? What gives Jeeves? The cartel is bailing before the "good news" hits lol!! It's all in the timing... I have to agree with the chartist here on the board who posted ... "Believe this could be an excellent spec buy right now."
Not because I believe in charts for penny stocks it's just that personally I tend to buy anytime it dips below 2 cents and I think ol Jeeves is gonna get lucky and call it right- someday. He/she has to- because you know the old saying 'bout the broken clock being correct twice a day...
Theo
LOL!!! I half expected to see Jeeves name at the end of that post... ;) ;)
NEWS: Interesting-
http://biz.yahoo.com/iw/060110/0105649.html
DNAPrint Genomics, Inc. Appoints Dr. Barbara Handelin as Director of Diagnostics
Tuesday January 10, 7:00 am ET
SARASOTA, FL--(MARKET WIRE)--Jan 10, 2006 -- DNAPrint(TM) Genomics, Inc. (OTC BB:DNAG.OB - News), announced today that it has appointed Barbara Handelin, Ph.D., as Director of Diagnostics, in the newly organized subsidiary, DNAPrint Pharmaceuticals, Inc. As Director, Dr. Handelin will be responsible for the commercialization of the Company's pharmacogenomics and personalized medicine products. Dr. Handelin is a seasoned biotech business executive and board certified Medical Geneticist (Molecular and Biochemical Genetics) with more than 18 years of experience in the application of genetics to clinical medicine and drug development research.
ADVERTISEMENT
Dr. Handelin was Director of the DNA Diagnostics Laboratory at Integrated Genetics (now Genzyme Genetics) starting in 1987 where she helped establish what became the largest commercial DNA testing laboratory in the world. Under her direction, the DNA Diagnostics laboratory was a technological and clinical practice leader in genetic diagnostics, setting the standard for low cost, high fidelity analysis of many mutations in genetically complex diseases and the first laboratory to offer commercial carrier and prenatal gene testing for Huntington's Disease (1987), Cystic Fibrosis (1990), Spinal Muscular Atrophy (1992), Tay Sachs Disease (1993 large scale carrier screening) and Fragile X (1994).
Since 1995, Dr. Handelin has provided business and technical consulting guidance for industry leaders in genetic diagnostics, pharmacogenetics, and drug development. Dr. Handelin has also served on a variety of federal committees and advisory panels on genetic testing and pharmacogenetics, including the Health and Human Services Secretary's Advisory Panel on Genetics, Health and Society and was the Principal Investigator on a DOE ELSI grant on the "The Responsibility of Oversight in Genetics Research: How to Enable Effective Human Subjects Review of Public and Privately Funded Research Programs." Dr. Handelin earned her Ph.D. at the Oregon Health Sciences University and the Massachusetts Institute of Technology.
"Dr. Handelin brings to DNAPrint extensive research and development expertise in the field of Diagnostics, which is crucial to DNAPrint Pharmaceuticals' future growth and development. We are very pleased to be working with her on the development of our diagnostic projects," said Hector J. Gomez, M.D., Ph.D., Chairman and Chief Medical Officer of DNAPrint Genomics, Inc. and the newly formed DNAPrint Pharmaceuticals, Inc.
"DNAPrint Pharmaceuticals is particularly fortunate to have Dr. Handelin lead our diagnostics division. She possesses the technical expertise and business savvy to develop and bring to market products which address significant market opportunities in an efficient and well executed manner," commented Richard Gabriel, President and CEO of DNAPrint.
About DNAPrint Genomics, Inc.
DNAPrint Genomics, Inc. (www.dnaprint.com) is a developer of genomics-based products and services in two primary markets: biomedical and forensics. DNAPrint Pharmaceuticals, Inc., a wholly owned subsidiary, develops diagnostic tests and theranostic products (drug/test combinations) using the Company's proprietary ancestry-informed genetic marker studies combined with proprietary computational modeling technology. Computational Biology and Pharmacogenomics services are also offered externally to biopharmaceutical companies. The Company's first theranostic product is PT-401, a "Super EPO" (erythropoietin) dimer protein drug for treatment of anemia in renal dialysis patients (end stage renal disease). Pre-clinical and clinical development of all the Company's drug candidates will benefit from simulated pre-trials to better design actual trials and are targeted to patients with a genetic profile indicating their propensity to have the best clinical response. DNAPrint is proud of its continued dedication to developing and supplying new technological advances in law enforcement and consumer ancestry heritage interests. Please refer to www.dnaprint.com for information on law enforcement and consumer applications which include DNAWITNESS(TM), RETINOME(TM), ANCESTRYbyDNA(TM) and EURO-DNA(TM).
Forward-Looking Statements
All statements in this press release that are not historical are forward-looking statements. Such statements are subject to risks and uncertainties that could cause actual results to differ materially from those projected, including, but not limited to, uncertainties relating to technologies, product development, manufacturing, market acceptance, cost and pricing of DNAPrint's products, dependence on collaborations and partners, regulatory approvals, competition, intellectual property of others, and patent protection and litigation. DNAPrint Genomics, Inc. expressly disclaims any obligation or undertaking to release publicly any updates or revisions to any forward-looking statements contained herein to reflect any change in DNAPrint's expectations with regard thereto or any change in events, conditions, or circumstances on which any such statements are based.
Contact:
Company Contact:
Richard Gabriel
CEO and President
941 366-3400
or
Ron Stabiner
The Wall Street Group, Inc.
212-888-4848
Somebody {?Teamlasvegas} posted earlier today that NITE was back sitting on the ASK. If you're not familiar, the MM NITE has historically been the leading "badboy" of pennyland MMs and has been busted and punished {if you can call a tongue-lashing "punishment"} many times over the years for various infractions involving penny stocks. Having NITE on the ASK means "he" is selling shares. Trust me, if NITE is selling, DNAG is being shorted. Naked? I don't have a clue. Doesn't matter as virtually EVERY stock out here has/is been shorted most likely by NITE at some time. My point is, when I watch level II or III and I see NITE on the BID, I take that as a "good" sign. If he is selling, I tend to be very skeptical. I'm not talking about intraday trading either. All MMs tend to bounce from the BID to the ASK depending on how fluid and active the stock is. I'm talking about when a MM is "setting up camp" on a particular side for an extended period.
JMHO
Theo
Thank you for your kind words Miss Scarlet,
You know, it's interesting in that moderators {not just here on DNAG either} are folks that are usually original/staunch supporters of the boards they represent. Yes, it is tough, especially when it is pretty much a given that your loyalties lay with the "pro" side. It becomes a fine line weighing what's "right" and all the time trying to maintain "balance". I just happened to be home this week {first time in 26 years I've been able to take this week off} and I can now fully appreciate what IVRT and Doug do during the day by cleaning up some if this before I even get home :)
Anyway, thanks again Miss Scarlet!
Theo
Btw, Flying really is my passion.
"Somebody figured it out by deleting 38930"
Well, without knowing what was in that post I guess we'll never know just what it was that "somebody figured out" now will we?
"Should I take my thank you back?"
You should probably ask the person to whom it applies would be my guess.
"Really the chip on your shoulder is becoming obvious now."
Clever Spitfire lol! But I'm not biting! Kinda like the "have you ever tasted sweeter socks than mine" Nope, not gonna draw me into a whizzing contest ... Go ahead I'll give you last word.
Theo
Just out of curiosity, what part of our recent exchange would you have me delete. Our verbal parlays are very similar to the ones seen here almost daily. So, which one{s} of our posts would you deem offensive enough to delete?
"Well somebody did"
Doesn't make your claim that I, in fact, deleted it any more valid though does it?
"Counting on the share price to help make a better board is ridiculous."
"Counting on it" was never stated or implied that that in and of itself was a solution merely a contributing factor to a poster's emotional status.
I deleted no such post
Why? He said FUD. Where do you suggest I or any moderator draw the line?
Tell me something Spitfire, do you suggest I delete FSAIL52's post just a minute ago?
"Why do the board monitors allow Fud to keep slandering the good doc's name?"